AptarGroup Reports Q4 2025 Earnings: 14% Sales Growth and 5% Core Sales Increase

viernes, 6 de febrero de 2026, 3:50 pm ET1 min de lectura
ATR--

AptarGroup reported Q4 2025 sales of $963 million, up 14%, and core sales up 5%. CEO Stephan Tanda emphasized "very strong top line performance." The company aims to improve margins by 2026 and target long-term pharma core sales growth of 7%–11%. However, the emergency medicine segment is facing headwinds.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios